Skip to main content
info

"Informed AI News" is an publications aggregation platform, ensuring you only gain the most valuable information, to eliminate information asymmetry and break through the limits of information cocoons. Find out more >>

Roche's Alectinib receives approval for new indication in the treatment of early-stage ALK-positive non-small cell lung cancer.

Alectinib by Roche, an ALK inhibitor, has now been approved for the treatment of early-stage ALK-positive non-small cell lung cancer (NSCLC). This is the first and only drug of its kind to receive such approval. The new indication has been officially approved by the National Medical Products Administration and is now on the market.

ALK inhibitor: A drug targeting ALK gene mutations, used for treating specific types of lung cancer.

Non-small cell lung cancer (NSCLC): A type of lung cancer that accounts for approximately 85% of all lung cancer cases.

Full article>>